الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 101 |  |  |
| | | from | 101 | | |
Abstract
RVO is the second most common retinal vascular disease after diabetic retinopathy, DR is the most widespread retinal vascular disease and the most prevalent cause of moderate and severe vision loss.
the development of ME in RVO is the most common cause of visual loss the production of VEGF, a hypoxia-induced endothelialcell-specific angiogenic and vaso permeable factor in patient with RVO cause a formation of ME and neovascularization some treatment such as intravitreal anti-VEGF injections and intravitreal dexamethasone injections have a good effect like good vision and anatomic outcomes.
The HRDs on SD-OCT are indicative of inflammation in the retina tear and are of equal or higher reflectivity than the RPE the good indicators such as the number of HRDs might predict the treatment response to anti-VEGF injections in patients with ME band.
So, our prospective, clinical trial was carried out to investigate the association between HRDs on spectral-domain optical coherence tomography (SD-OCT) and response to intravitreal Ramizumab (Luceints) in eyes with macular edema due to RVO.
This study was carried put on 40 eye with ME due to RVO who were recruited in the outpatient clinics in Menoufia University.
Including, patients aged 20-70 of both genders, with treatment naïve eyes with ME due to RVO, their IOP 12-22 mmHg,
Excluding, patients with high myopia (>8 diopters), glaucoma, media opacities due to cataract or corneal disease, vitreous hemorrhage, combined retinal disease, or their SD-OCT images were of poor quality.
Each studied participant was subjected to preoperative assessment followed by 3 injection (one injection monthly for 3 months), after good sterilization all patient with ME were treated with Rmivzemab (lucent) 0.1 ml from 4 mg monthly for 3 months.
Then post-operative assessment was done as follow-up of the patient: (at one day post-operative after each injection, every month for 3 months, and one month after the last injection), full medical and ophthalmic examination, clinical examination including BCVA, slitlamp examination, fundus examination, IOP measurement, and investigation by SD-OCT one month after the last injection to show HRD number size extent with in an area of1500um radius centered on the fovea, macular thickness or any pathology.